Clover highlights preclinical data for COVID-19 vaccine candidate

By The Science Advisory Board staff writers

May 18, 2021 -- Clover Biopharmaceuticals said that its second-generation, protein-based COVID-19 vaccine candidate has demonstrated in preclinical testing that it can provide broad neutralization of the original SARS-CoV-2 strain as well as variants of concern.

Mice that were vaccinated with two doses of the modified B.1.351 Spike (S)-Trimer at day 0 and day 21 showed strong humoral immune responses that broadly neutralize the original SARS-CoV-2 variants first identified in South Africa (B.1.351), Brazil (P.1), and the U.K. (B.1.1.7), according to Clover.

In other results, the researchers reported that immunization with two doses of Clover's SCB-2019 first-generation vaccine candidate and a third booster dose on day 35 of either SCB-2019 or B.1.351 S-Trimer increased cross-reactive neutralizing antibodies against B.1.351. These findings demonstrate the potential importance of booster doses, according to Clover.

The research is available as a preprint on bioRxiv and also will be submitted for a peer-review publication, the company said. Clover said it intends to continue evaluation of B.1.351 S-Trimer and advance a second-generation COVID-19 vaccine candidate into clinical trials in the second half of 2021.

Clover, Dynavax begin COVID-19 vaccine late-stage trials
Clover Biopharmaceuticals and Dynavax announced they have begun a phase II/III clinical trial to evaluate the efficacy of Clover's protein-based S-Trimer...
Cytiva helps Clover scale up biomanufacturing of COVID-19 vaccine
Clover Biopharmaceuticals is working with Cytiva to scale up the company's COVID-19 vaccine manufacturing capabilities.
Clover touts positive preclinical results for COVID-19 vaccine
Clover Biopharmaceuticals has announced positive preclinical data regarding its protein-based COVID-19 S-Trimer vaccine candidate in combination with...
CEPI expands Clover partnership on COVID-19 vaccine
The Coalition for Epidemic Prepardeness Innovations (CEPI) has expanded its partnership with Clover Biopharmaceuticals for the development and manufacture...
CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter